238 related articles for article (PubMed ID: 28775095)
1. Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.
Penumatsa KC; Toksoz D; Warburton RR; Kharnaf M; Preston IR; Kapur NK; Khosla C; Hill NS; Fanburg BL
Am J Physiol Lung Cell Mol Physiol; 2017 Nov; 313(5):L752-L762. PubMed ID: 28775095
[TBL] [Abstract][Full Text] [Related]
2. Glycolysis regulated transglutaminase 2 activation in cardiopulmonary fibrogenic remodeling.
Bhedi CD; Nasirova S; Toksoz D; Warburton RR; Morine KJ; Kapur NK; Galper JB; Preston IR; Hill NS; Fanburg BL; Penumatsa KC
FASEB J; 2020 Jan; 34(1):930-944. PubMed ID: 31914588
[TBL] [Abstract][Full Text] [Related]
3. Lung-specific interleukin 6 mediated transglutaminase 2 activation and cardiopulmonary fibrogenesis.
Penumatsa KC; Sharma Y; Warburton RR; Singhal A; Toksoz D; Bhedi CD; Qi G; Preston IR; Anderlind C; Hill NS; Fanburg BL
Front Immunol; 2024; 15():1371706. PubMed ID: 38650935
[TBL] [Abstract][Full Text] [Related]
4. Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation.
Penumatsa KC; Toksoz D; Warburton RR; Hilmer AJ; Liu T; Khosla C; Comhair SA; Fanburg BL
Am J Physiol Lung Cell Mol Physiol; 2014 Oct; 307(7):L576-85. PubMed ID: 25128524
[TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Matrix Cross-Linking Enhances Fibroblast Growth and Protects against Matrix Proteolysis in Lung Fibrosis.
Philp CJ; Siebeke I; Clements D; Miller S; Habgood A; John AE; Navaratnam V; Hubbard RB; Jenkins G; Johnson SR
Am J Respir Cell Mol Biol; 2018 May; 58(5):594-603. PubMed ID: 29053339
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 and its role in pulmonary fibrosis.
Olsen KC; Sapinoro RE; Kottmann RM; Kulkarni AA; Iismaa SE; Johnson GV; Thatcher TH; Phipps RP; Sime PJ
Am J Respir Crit Care Med; 2011 Sep; 184(6):699-707. PubMed ID: 21700912
[TBL] [Abstract][Full Text] [Related]
8. Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice.
DiRaimondo TR; Klöck C; Warburton R; Herrera Z; Penumatsa K; Toksoz D; Hill N; Khosla C; Fanburg B
ACS Chem Biol; 2014 Jan; 9(1):266-75. PubMed ID: 24152195
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
[TBL] [Abstract][Full Text] [Related]
10. Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling.
Chen YF; Feng JA; Li P; Xing D; Zhang Y; Serra R; Ambalavanan N; Majid-Hassan E; Oparil S
J Appl Physiol (1985); 2006 Feb; 100(2):564-71. PubMed ID: 16223981
[TBL] [Abstract][Full Text] [Related]
11. TRPV4 channel mediates adventitial fibroblast activation and adventitial remodeling in pulmonary hypertension.
Cussac LA; Cardouat G; Tiruchellvam Pillai N; Campagnac M; Robillard P; Montillaud A; Guibert C; Gailly P; Marthan R; Quignard JF; Savineau JP; Ducret T
Am J Physiol Lung Cell Mol Physiol; 2020 Jan; 318(1):L135-L146. PubMed ID: 31693393
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload.
Shinde AV; Su Y; Palanski BA; Fujikura K; Garcia MJ; Frangogiannis NG
J Mol Cell Cardiol; 2018 Apr; 117():36-48. PubMed ID: 29481819
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase promotes serotonin-induced AKT signaling and mitogenesis in pulmonary vascular smooth muscle cells.
Penumatsa K; Abualkhair S; Wei L; Warburton R; Preston I; Hill NS; Watts SW; Fanburg BL; Toksoz D
Cell Signal; 2014 Dec; 26(12):2818-25. PubMed ID: 25218191
[TBL] [Abstract][Full Text] [Related]
14. The redox state of transglutaminase 2 controls arterial remodeling.
van den Akker J; VanBavel E; van Geel R; Matlung HL; Guvenc Tuna B; Janssen GM; van Veelen PA; Boelens WC; De Mey JG; Bakker EN
PLoS One; 2011; 6(8):e23067. PubMed ID: 21901120
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
16. Serotonylated fibronectin is elevated in pulmonary hypertension.
Wei L; Warburton RR; Preston IR; Roberts KE; Comhair SA; Erzurum SC; Hill NS; Fanburg BL
Am J Physiol Lung Cell Mol Physiol; 2012 Jun; 302(12):L1273-9. PubMed ID: 22523280
[TBL] [Abstract][Full Text] [Related]
17. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor.
Wang Z; Stuckey DJ; Murdoch CE; Camelliti P; Lip GYH; Griffin M
Cell Death Dis; 2018 Apr; 9(6):613. PubMed ID: 29795262
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 is secreted from smooth muscle cells by transamidation-dependent microparticle formation.
van den Akker J; van Weert A; Afink G; Bakker EN; van der Pol E; Böing AN; Nieuwland R; VanBavel E
Amino Acids; 2012 Feb; 42(2-3):961-73. PubMed ID: 21830119
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary vascular collagen content, not cross-linking, contributes to right ventricular pulsatile afterload and overload in early pulmonary hypertension.
Wang Z; Schreier DA; Abid H; Hacker TA; Chesler NC
J Appl Physiol (1985); 2017 Feb; 122(2):253-263. PubMed ID: 27856711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
